News | October 25, 2025
Syngene International expands capabilities with new bioconjugation suite in Bengaluru
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
Revenues up 13.1% year-over-year; Continued momentum driven by organic growth, strategic partnerships, and acquisitions
Nicardipine Hydrochloride in 0.9% Sodium Chloride Injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable
The product is indicated for the chronic management of patients with Urea Cycle Disorders
Glenmark’s Ropivacaine Hydrochloride Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug Naropin Injection of Fresenius Kabi USA
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
Yesintek and Yesintek I.V. are approved for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients
Adding one year of Imfinzi treatment to Bacillus Calmette-Guérin (BCG) induction and maintenance therapy delivered an early and sustained disease-free survival benefit vs. BCG alone
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
Subscribe To Our Newsletter & Stay Updated
